{"id":"https://openalex.org/W2019103756","doi":"https://doi.org/10.1055/s-0033-1363993","title":"Non-Clinical Pharmacokinetic/Pharmacodynamic and Early Clinical Studies Supporting Development of a Novel Subcutaneous Formulation for the Monoclonal Antibody Rituximab","display_name":"Non-Clinical Pharmacokinetic/Pharmacodynamic and Early Clinical Studies Supporting Development of a Novel Subcutaneous Formulation for the Monoclonal Antibody Rituximab","publication_year":2014,"publication_date":"2014-01-22","ids":{"openalex":"https://openalex.org/W2019103756","doi":"https://doi.org/10.1055/s-0033-1363993","mag":"2019103756","pmid":"https://pubmed.ncbi.nlm.nih.gov/24452524"},"language":"en","primary_location":{"id":"doi:10.1055/s-0033-1363993","doi":"https://doi.org/10.1055/s-0033-1363993","is_oa":true,"landing_page_url":"https://doi.org/10.1055/s-0033-1363993","pdf_url":"http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0033-1363993.pdf","source":{"id":"https://openalex.org/S4210226141","display_name":"Drug Research","issn_l":"2194-9379","issn":["2194-9379","2194-9387"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","medline","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320000","host_organization_name":"Thieme Medical Publishers (Germany)","host_organization_lineage":["https://openalex.org/P4310320000"],"host_organization_lineage_names":["Thieme Medical Publishers (Germany)"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Research","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0033-1363993.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5008248783","display_name":"Beate Bittner","orcid":"https://orcid.org/0000-0002-8126-116X","observed_orcids":["https://orcid.org/0000-0002-8126-116X"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"B. Bittner","raw_affiliation_strings":["F. Hoffmann-La Roche Ltd., Product Optimization, Basel, Switzerland","F. Hoffmann-La Roche Ltd., Clinical Pharmacology, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd., Product Optimization, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]},{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd., Clinical Pharmacology, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048684851","display_name":"W. Richter","orcid":"https://orcid.org/0000-0002-8094-8605","observed_orcids":["https://orcid.org/0000-0002-8094-8605"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"W. Richter","raw_affiliation_strings":["F. Hoffmann-La Roche Ltd., Non-clinical Safety, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd., Non-clinical Safety, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042799528","display_name":"Florence Hourcade\u2010Potelleret","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"F. Hourcade-Potelleret","raw_affiliation_strings":["F. Hoffmann-La Roche Ltd., Clinical Modeling & Simulation, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd., Clinical Modeling & Simulation, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007078235","display_name":"Frank Herting","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"F. Herting","raw_affiliation_strings":["Roche Diagnostics GmbH, Penzberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Roche Diagnostics GmbH, Penzberg, Germany","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5053315132","display_name":"Johannes Schmidt","orcid":"https://orcid.org/0000-0002-5340-8611","observed_orcids":["https://orcid.org/0000-0002-5340-8611"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":true,"raw_author_name":"J. Schmidt","raw_affiliation_strings":["F. Hoffmann-La Roche Ltd., Product Optimization, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd., Product Optimization, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5053315132"],"corresponding_institution_ids":["https://openalex.org/I118019719"],"apc_list":null,"apc_paid":null,"fwci":2.1834,"has_fulltext":true,"cited_by_count":32,"citation_normalized_percentile":{"value":0.88271299,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":98},"biblio":{"volume":"64","issue":"11","first_page":"569","last_page":"575"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.49320000410079956,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.49320000410079956,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.3903999924659729,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.04769999906420708,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":1.0},{"id":"https://openalex.org/keywords/subcutaneous-formulation","display_name":"subcutaneous formulation","score":0.9890000224113464},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.8080000281333923},{"id":"https://openalex.org/keywords/cd20","display_name":"CD20","score":0.7699999809265137},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8650000095367432},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9729999899864197},{"id":"https://openalex.org/keywords/dose-finding","display_name":"dose-finding","score":0.6460000276565552},{"id":"https://openalex.org/keywords/b-cell-depletion","display_name":"B-cell depletion","score":0.7260000109672546},{"id":"https://openalex.org/keywords/follicular-lymphoma","display_name":"follicular lymphoma","score":0.8149999976158142},{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9959999918937683},{"id":"https://openalex.org/keywords/receptor-saturation","display_name":"receptor saturation","score":0.6610000133514404},{"id":"https://openalex.org/keywords/non-inferiority","display_name":"non-inferiority","score":0.7089999914169312}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8165286779403687},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7540518045425415},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.7506275177001953},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.6324089765548706},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5515300631523132},{"id":"https://openalex.org/C2777058707","wikidata":"https://www.wikidata.org/wiki/Q123251","display_name":"Follicular lymphoma","level":3,"score":0.5512213110923767},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.5367283821105957},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.5130616426467896},{"id":"https://openalex.org/C18031839","wikidata":"https://www.wikidata.org/wiki/Q5009796","display_name":"CD20","level":3,"score":0.5107128620147705},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.4530855417251587},{"id":"https://openalex.org/C2776390293","wikidata":"https://www.wikidata.org/wiki/Q2035485","display_name":"Subcutaneous injection","level":2,"score":0.42033934593200684},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.4123353362083435},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.34604668617248535},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.32658326625823975},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2811509370803833},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.25725123286247253},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.23289251327514648}],"mesh":[{"descriptor_ui":"D000069283","descriptor_name":"Rituximab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002626","descriptor_name":"Chemistry, Pharmaceutical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007279","descriptor_name":"Injections, Subcutaneous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058846","descriptor_name":"Antibodies, Monoclonal, Murine-Derived","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D058846","descriptor_name":"Antibodies, Monoclonal, Murine-Derived","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D058846","descriptor_name":"Antibodies, Monoclonal, Murine-Derived","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1055/s-0033-1363993","doi":"https://doi.org/10.1055/s-0033-1363993","is_oa":true,"landing_page_url":"https://doi.org/10.1055/s-0033-1363993","pdf_url":"http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0033-1363993.pdf","source":{"id":"https://openalex.org/S4210226141","display_name":"Drug Research","issn_l":"2194-9379","issn":["2194-9379","2194-9387"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","medline","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320000","host_organization_name":"Thieme Medical Publishers (Germany)","host_organization_lineage":["https://openalex.org/P4310320000"],"host_organization_lineage_names":["Thieme Medical Publishers (Germany)"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Research","raw_type":"journal-article"},{"id":"pmid:24452524","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24452524","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug research","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1055/s-0033-1363993","doi":"https://doi.org/10.1055/s-0033-1363993","is_oa":true,"landing_page_url":"https://doi.org/10.1055/s-0033-1363993","pdf_url":"http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0033-1363993.pdf","source":{"id":"https://openalex.org/S4210226141","display_name":"Drug Research","issn_l":"2194-9379","issn":["2194-9379","2194-9387"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","medline","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320000","host_organization_name":"Thieme Medical Publishers (Germany)","host_organization_lineage":["https://openalex.org/P4310320000"],"host_organization_lineage_names":["Thieme Medical Publishers (Germany)"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Research","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2019103756.pdf","grobid_xml":"https://content.openalex.org/works/W2019103756.grobid-xml"},"referenced_works_count":12,"referenced_works":["https://openalex.org/W1906683030","https://openalex.org/W1906911561","https://openalex.org/W1997578973","https://openalex.org/W2001161794","https://openalex.org/W2015186160","https://openalex.org/W2017264099","https://openalex.org/W2046150302","https://openalex.org/W2112785451","https://openalex.org/W2144063308","https://openalex.org/W2158548553","https://openalex.org/W2556823464","https://openalex.org/W4238520503"],"related_works":["https://openalex.org/W2112785451","https://openalex.org/W2074118258","https://openalex.org/W2620735312","https://openalex.org/W2120711586","https://openalex.org/W2011450437","https://openalex.org/W2154839397","https://openalex.org/W2762891584","https://openalex.org/W2611645469","https://openalex.org/W2555805497","https://openalex.org/W3165470995"],"abstract_inverted_index":{"This":[0],"overview":[1],"article":[2],"describes":[3],"the":[4,13,63,66,71,99,107,143,155,189,195],"non-clinical":[5,55,149],"pharmacology,":[6],"pharmacokinetic":[7,140],"and":[8,42,56,116,126,203],"clinical":[9,57],"dose-finding":[10],"programs":[11],"supporting":[12],"development":[14],"of":[15,33,110,169,175],"a":[16,22],"novel":[17,72],"subcutaneous":[18,31,73,84,127],"formulation":[19,69,101],"for":[20,40,78,154],"rituximab,":[21],"monoclonal":[23],"antibody":[24],"that":[25,82,89,129],"selectively":[26],"targets":[27],"CD20-positive":[28],"B-lymphocytes.":[29],"The":[30,75],"route":[32],"administration":[34],"is":[35],"expected":[36],"to":[37,43,61,70,133,181,188],"improve":[38],"convenience":[39],"patients":[41,163,199],"reduce":[44],"healthcare":[45],"professional":[46],"resource":[47],"use":[48],"compared":[49],"with":[50,98,164,200],"conventional":[51],"intravenous":[52,68,100,125,190],"infusion.":[53],"Various":[54],"studies":[58,80,121,141],"were":[59,122,130],"conducted":[60],"support":[62],"bridge":[64],"from":[65,147],"approved":[67],"treatment.":[74,171],"underlying":[76],"hypothesis":[77],"these":[79,148],"was":[81,179],"achieving":[83],"rituximab":[85],"serum":[86,137,185],"trough":[87,186],"concentrations":[88,138,187],"are":[90,207],"at":[91,105,124],"least":[92,106],"as":[93,95,167],"high":[94],"those":[96],"reached":[97],"would":[102],"result":[103,134,182],"in":[104,135,139,142,162,183,194,198],"same":[108,144],"degree":[109],"receptor":[111],"saturation.":[112],"Preclinical":[113],"mouse":[114],"xenograft":[115],"cynomolgus":[117],"monkey":[118],"B-cell":[119],"depletion":[120],"performed":[123],"doses":[128],"previously":[131],"found":[132,180],"comparable":[136],"species.":[145],"Results":[146],"assessments":[150],"guided":[151],"dose":[152,159,174],"selection":[153],"subsequent":[156],"phase":[157],"1b":[158],"finding":[160],"trials":[161,193],"follicular":[165,201],"lymphoma":[166,202],"part":[168],"maintenance":[170],"A":[172],"fixed":[173],"1":[176],"400":[177],"mg":[178],"noninferior":[184],"formulation.":[191],"Clinical":[192],"induction":[196],"setting":[197],"chronic":[204],"lymphocytic":[205],"leukemia":[206],"currently":[208],"ongoing.":[209]},"counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":6},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}